BioNexus Gene Lab Corp (BGLC) FinancialsBGLCFinancialBioNexus Gene Lab Corp

BioNexus Gene Lab Corp (BGLC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Chemrex, accounting for 99.9% of total sales, equivalent to $2.13M. Another important revenue stream is BioNexus Malaysisa. Understanding this composition is critical for investors evaluating how BGLC navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, BioNexus Gene Lab Corp maintains a gross margin of 17.05%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -398.69%, while the net margin is -376.14%. These profitability ratios, combined with a Return on Equity (ROE) of -33.66%, provide a clear picture of how effectively BGLC converts its operational activities into shareholder value.

In the context of the broader market, BGLC competes directly with industry leaders such as CHNR and CAPS. With a market capitalization of $4.55M, it holds a significant position in the sector. When comparing efficiency, BGLC's gross margin of 17.05% stands against CHNR's N/A and CAPS's 27.93%. Such benchmarking helps identify whether BioNexus Gene Lab Corp is trading at a premium or discount relative to its financial performance.

The company's total revenue for Q2 2026 was 76156, a significant drop from previous quarters, indicating ongoing financial struggles. However, the gross margin improved to 17.05% in Q2 2026, showing some operational efficiency.